A Twenty-years' Experience in Pituitary Disease.

Recruiting

• Conditions: Pituitary Adenoma; Pituitary Cancer; Pituitary Disease

• Registration Number: NCT06973824
• Lead Sponsor: Fondazione Policlinico Universitario Agostino Gemelli IRCCS

Brief Summary

Pituitary tumors represent a heterogeneous group of neoplasms by histotype. The pituitary adenomas are the most frequent heteroformation, among those affecting the pituitary gland, followed by meningiomas, craniopharyngiomas, germosomes and tumours secondary, such as metastases and lymphomas. Since these conditions are considered rare, the data epidemiology and prognosis to predict the natural history of these diseases can not be considered conclusive. Pituitary adenomas are a useful model for epidemiology in the study of pathology pituitary. Over the past 20 years, several attempts have been made to identify unique prognostic factors, which predict the outcome of these pathologies, but without To arrive at a definitive classification. The purpose of this study aims to collect clinical, biochemical, morphological and pathological data on the retrospective and prospective cohort of over 1600 patients undergoing neurosurgical removal of pituitary tumors in the last 20 years, to develop a prognostic classification.

Detailed Description

Not available

Study Timeline

• Study First Submitted: 2025-01-22
• Study Start: 2025-03-10
• Status Verified: 2025-05
• Study First Submitted QC: 2025-05-07
• Last Update Submitted: 2025-05-07
• Study First Posted: 2025-05-15
• Last Update Posted: 2025-05-15
• Primary Completion: 2028-02-15
• Study Completion: 2028-04-30

Recruitment & Eligibility

• Status: RECRUITING
• Sex: All
• Target Recruitment: 1600

Inclusion Criteria

• Patients underwent surgery for pituitary tumors;
• pathology diagnosis of pituitary tumors;
• patients older then 18 years at diagnosis of pituitary tumors;
• 2 years follow-up;

Exclusion Criteria

• age lower then 18 years
• follow-up shorter than 2 years

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Tumor recurrence	From enrollement to last observation at 24 months of follow-up	Frequency of tumor recurrence at 24 months of follow-up

Trial Locations

Locations (1)

Fondazione Policlinico Gemelli IRCCS; 🇮🇹 Rome, IT, Italy